CLIP1-LTK融合は,非小細胞肺がんにおける腫瘍発生因子である

Hiroki Izumi¹, Shingo Matsumoto¹, Jie Liu²

¹Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Nature

|November 25, 2021

まとめ

研究者は,非小細胞肺がん (NSCLC) で新しいCLIP1-LTK融合を発見した. この融合はロラチニブで標的となり,他の既知の駆動因子が欠けているNSCLC患者の新たな治療法となる可能性がある.

科学分野:

腫瘍学
分子生物学
ゲノミクス

背景:

非小細胞肺がん (NSCLC) の治療は標的型療法によって改善されています.
しかし,肺アデノカルシノーマの症例の有意な部分は,特定された腫瘍発生要因が欠けている.
これはNSCLCにおける新しい治療目標の必要性を強調しています.

研究の目的:

NSCLCにおける新たな発がん要因を特定する.
特定された合併を標的とした治療の可能性を調査する.
新しいNSCLCに対するロラチニブの有効性を評価する.

主な方法:

多機構のゲノムスクリーニングプラットフォームを使用して全トランスクリプトームシーケンスが採用されました.
CLIP1-LTK融合が特定され,特徴づけられました.
Ba/ F3細胞で機能分析を行い,患者のケーススタディを分析した.

主要な成果:

新しいCLIP1- LTK融合トランスクリプトは,既知のドライバーと相互排斥するNSCLCの0. 4%で特定されました.
CLIP1-LTK融合タンパク質は構成キナーゼの活性と変換の可能性を示しています.
ローラチニブはCLIP1- LTKの活性を効果的に抑制し,増殖を抑制し,アポトーシスをインビトロで誘導した.
CLIP1- LTK融合が宿るNSCLCの患者はロラチニブに良好な反応を示した.

結論:

CLIP1- LTK融合は,NSCLCにおける新たに特定された腫瘍発生因子である.
この融合は,がんにおける腫瘍性活性を持つLTK変異を初めて記述した.
CLIP1- LTK融合は,ロラチニブで治療可能なNSCLCの潜在的な治療目標です.

さらに関連する動画

06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.9K

関連する概念動画

02:39

lncRNA - Long Non-coding RNAs

9.0K

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

9.0K

01:33

Cancer-Critical Genes I: Proto-oncogenes

9.3K

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

9.3K

02:57

Targeted Cancer Therapies

7.9K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.9K

01:06

Induced Pluripotent Stem Cells

4.5K

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

4.5K

01:12

Loss of Tumor Suppressor Gene Functions

5.2K

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...